Crossmark

Failure to predict amikacin elimination in critically ill patients with cancer based on the estimated glomerular filtration rate: applying PBPK approach in a therapeutic drug monitoring study

Crossref DOI link: https://doi.org/10.1007/s00228-023-03516-1

Published Online: 2023-05-31

Published Print: 2023-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Telles, João Paulo

Diegues, Mariana Suelotto

Migotto, Karen Cristina

de Souza Borges, Olivia

Reghini, Rodrigo

Gavazza, Brenda Vianna

Pinto, Leonardo

Caruso, Pedro

e Silva, Ivan Leonardo França

Schmidt, Stephan

de Lima Moreira, Fernanda
License Information

Text and Data Mining valid from 2023-05-31

Version of Record valid from 2023-05-31
More Information

Article History

Received: 28 February 2023

Accepted: 22 May 2023

First Online: 31 May 2023

Declarations

:

: This study was approved by the Research Ethics Committee of AC Camargo Cancer Center (CAE 56419722.0.0000.5432).

: Not applicable: retrospective study.

: Not applicable: retrospective study.

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below